Progestin-only pills (POPs) represent a key advancement in hormonal contraception by offering an estrogen-free alternative suitable for a diverse range of women, including those who are breastfeeding or have contraindications to estrogens. First introduced in the 1970s with norethisterone-based formulations, the evolution of POPs has been driven by the need for improved efficacy and tolerability. Modern progestins such as desogestrel and drospirenone have demonstrated superior ovulation inhibition rates, reaching over 99% with perfect use, and present a more favorable side effect profile, particularly regarding androgenic effects. The mechanisms of action of POPs include ovulation suppression, increased viscosity of cervical mucus, and endometrial transformation, all contributing to their contraceptive effectiveness. Desogestrel offers robust ovulation inhibition with low androgenic activity, while drospirenone adds antimineralocorticoid benefits, enhancing fluid retention control and premenstrual symptom management. Phase III studies have confirmed the high contraceptive efficacy and cardiovascular safety of these progestins. Despite their slightly lower efficacy in typical-use scenarios compared to combined oral contraceptives (COCs), POPs provide a critical option for individualized contraceptive care, aligning with the broader goals of women’s health empowerment and reproductive autonomy. Future research is expected to further optimize POP formulations, aiming to enhance adherence, minimize side effects, and expand contraceptive options for women worldwide.